A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome

Brief description of study

The purpose of this study is to test two different dose levels of ARO-APOC3 administered 4 times, 3 months apart in people with Familial Chylomicronemia Syndrome (FCS). The intention is to test the efficacy and safety of ARO-APOC3, as well as the pharmacokinetics (PK - how your body uses the study drug) and pharmacodynamics (PD - how the study drug affects your body) of the study drug. ARO-APOC3 is an experimental drug. This means that it is not approved by the United States Food and Drug Administration (FDA) for marketing. While ARO-APOC3 has already been tested in healthy participants and participants with hypertriglyceridemia, the potential therapeutic benefits and side effects in people with FCS are still being studied.

Clinical Study Identifier: s21-01153
ClinicalTrials.gov Identifier: NCT05089084

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.